ArticleBMC endocrine disorders2026
Serum β2-microglobulin, cystatin-C, and urinary KIM-1 as predictors of early renal impairment in women with diabetes in pregnancy: a prospective cohort study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes in pregnancy (DIP), including pregestational diabetes mellitus (PGDM) and gestational diabetes mellitus (GDM), increases the risk of early renal impairment. However, conventional renal markers are often insensitive in the early stages. Emerging biomarkers—serum β2-microglobulin (β2-MG), Cystatin-C (CysC), and urinary kidney injury molecule-1 (KIM-1)—may enhance early detection. This study aimed to evaluate the diagnostic and predictive value of β2-MG, CysC, and KIM-1 for early renal impairment in women with DIP using longitudinal, survival, and mediation analyses.
methodsIn this prospective cohort study, 360 women with DIP were followed at four visits: mid-pregnancy, late pregnancy, delivery, and 6 months postpartum. Serum β2-MG, CysC, and urinary KIM-1 were measured longitudinally. Early renal impairment was defined as a urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g or a ≥ 10% decline in estimated glomerular filtration rate (eGFR). Logistic regression, receiver operating characteristic analyses, time-dependent Cox proportional hazards models, and mediation analyses were conducted to evaluate predictive performance and potential pathways.
resultsSeventy-two women (20.0%) developed early renal impairment. Baseline levels of β2-MG (2.41 ± 0.35 vs. 1.82 ± 0.29 mg/L), CysC (1.05 ± 0.15 vs. 0.85 ± 0.12 mg/L), and KIM-1 (3.42 ± 0.71 vs. 1.91 ± 0.52 ng/mg Cr) were significantly higher in affected participants (all P < 0.001). All three biomarkers independently predicted renal impairment (adjusted odds ratios: β2-MG 2.15; CysC 1.92; KIM-1 2.78). A combined model incorporating clinical variables and all biomarkers achieved the highest discrimination (AUC = 0.90; sensitivity 83.3%; specificity 81.9%). In time-dependent Cox analyses, elevated biomarker levels were associated with earlier onset of renal impairment (adjusted hazard ratios: β2-MG 1.87; CysC 1.72; KIM-1 2.41). Biomarkers mediated 24–34% of the association between glycated hemoglobin (HbA1c) and renal impairment. Longitudinal trajectories showed progressive increases during pregnancy, peaking at delivery and partially declining postpartum, with individuals exhibiting persistently high levels remaining at elevated risk.
conclusionsSerum β2-MG, CysC, and urinary KIM-1 are independent predictors of early renal impairment in women with DIP. Their combined assessment substantially improves early risk stratification beyond conventional renal markers. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.